Biosimilars: Company Strategies to Capture Value from the Biologics Market

Pharmaceuticals

Bruno Calo-Fernández¹ 

[1]Escuela Técnica Superior de Ingeniería, Universidad de Santiago de Compostela, Rúa Lope Gómez de Marzoa s/n, Campus Vida 15782, Santiago de Compostela, Spain

关键词: biosimilar;    patent cliff;    biopharmaceutical industry;    market strategy;    biologics;   

DOI  :  10.3390/ph5121393

来源: mdpi

【 摘 要 】

Patents for several biologic blockbusters will expire in the next few years. The arrival of biosimilars, the biologic equivalent of chemical generics, will have an impact on the current biopharmaceuticals market. Five core capabilities have been identified as paramount for those companies aiming to enter the biosimilars market: research and development, manufacturing, supporting activities, marketing, and lobbying. Understanding the importance of each of these capabilities will be key to maximising the value generated from the biologics patent cliff.

【 授权许可】

CC BY   
© 2012 by the authors; licensee MDPI, Basel, Switzerland.